Receptor Interacting Protein 2 (rip2) in Development of Immune Response

Tech ID: 20537 / UC Case 2001-425-0

INNOVATION

UCLA investigators have determined that Receptor Interacting Protein 2 (RIP2) has novel functions in regulating Th1 helper T cells and the IL-1/IL-18 Toll-like receptor responses of NK cells and presents a target for therapeutic approaches to the treatment of disorders mediated by these cells, including toxic shock and certain autoimmune diseases. Their results suggest that RIP2 plays a pivotal role in Th1 and NK cell-mediated immune responses and that its regulation should provide a therapeutic approach to the treatment of disorders mediated by these cells, such as toxic shock and of certain autoimmune diseases.

PATENT STATUS

Country	Type	Number	Dated	Case
Patent Cooperation Treaty	Reference for National Filings	WO 03/023393 A1	03/20/2003	2001-425

Patent Pending

CONTACT

UCLA Technology Development Group
ncd@tdg.ucla.edu
tel: 310.794.0558.

INVENTORS

- Cheng, Genhong

OTHER INFORMATION

KEYWORDS

therapeutics, research tools

CATEGORIZED AS

- **Research Tools**
  - Reagents
  - Screening Assays

RELATED CASES

2001-425-0

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- Broad Antiviral Therapy with Membrane-Modifying Small Molecules

UCLA Technology Development Group
10889 Wilshire Blvd., Suite 920,Los Angeles,CA 90095
https://tdg.ucla.edu
Tel: 310.794.0558 | Fax: 310.794.0638 | ncd@tdg.ucla.edu